Acronym:
SEAGEN SGNLVA
ACTRN/NCT /ethics:
NCT04032704
Scientific title:
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Summary of trial and patient characteristics
| Cancer Type | All cancers, Lung & mesothelioma, Head and Neck, Stomach & Oesophageal | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II | Tumour Stream | Solid tumours |
| Age Range | 18 years and older | Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Sex | Both | Anticipated Start Date | 2019-10-09 |
| Molecular Target | Anticipated End Date | 2021-04-30 | |
| Cancer Type | All cancers, Lung & mesothelioma, Head and Neck, Stomach & Oesophageal |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Solid tumours |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2019-10-09 |
| Anticipated End Date | 2021-04-30 |
Trial Summary
This trial will study Ladiratuzumab Vedotin (LV) to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur.
Lay Summary
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Sponsor / Cooperative group
Seattle Genetics, Inc.
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Dr Chris Karapetis | Not Yet Recruiting |